As of June 17, 2025, Transgene SA (TNG.PA) reports a Net Margin of -292.48%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Transgene SA's Net Margin
Over recent years, Transgene SA's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -292.48% |
| 2022-12-31 | -327.97% |
| 2021-12-31 | -114.82% |
| 2020-12-31 | -184.43% |
| 2019-12-31 | -141.43% |
This slight downward trend highlights how Transgene SA manages its overall profitability and cost control over time.
Comparing Transgene SA's Net Margin to Peers
To better understand Transgene SA's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Transgene SA (TNG.PA) | -292.48% |
| Addex Therapeutics Ltd (ADXN.SW) | 1720.76% |
| Nanobiotix SA (NANO.PA) | 586.89% |
| Bonesupport Holding AB (BONEX.ST) | 14.88% |
| Circassia Group PLC (CIR.L) | 12.90% |
| Synthaverse SA (BML.WA) | 12.07% |
Compared to its competitors, Transgene SA's Net Margin is about average compared to peers, reflecting typical industry profitability.